| 02/02 | Chinese Regulator Accepts Junshi Bio's New Drug Application for Hyperlipidemia Treatmen.. |  |
| 02/02 | Zhejiang Huahai Pharma to Supply APIs to Junshi Biosciences | |
| 01/02 | Shanghai Junshi Biosciences Unit Signs Manufacturing, Supply Deal for Anti-COVID-19 Dru.. | |
| 31/01 | Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance.. | |
| 31/01 | Shanghai Junshi Bio to Widen 2022 Loss as R&D Expenses Balloon | |
| 30/01 | Junshi Biosciences Announces Approval for Marketing of VV116 in China | |
| 30/01 | Shanghai Junshi Biosciences Co., Ltd. Announces Approval for Marketing of VV116 in Chin.. | |
| 30/01 | Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended Dec.. | |
| 30/01 | China Issues Conditional Approval For Two Local COVID-19 Drugs | |
| 29/01 | China approves two domestically developed COVID drugs | |
| 18/01 | Junshi Biosciences Announces Acceptance of NDA for VV116 in China | |
| 18/01 | Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China | |
| 18/01 | Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC .. | |
| 18/01 | Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC .. | |
| 18/01 | Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC .. | |
| 18/01 | China Accepts Junshi Bioscience's New Drug Application for COVID-19 Drug | |
| 18/01 | Shanghai Junshi Biosciences' Phase III Study for Lung Cancer Treatment Meets Primary En.. | |
| 11/01 | Shanghai Junshi Biosciences Obtains Regulatory Approval for Adalimumab Supplemental Dru.. | |
| 03/01 | Shanghai Junshi Biosciences Completes Phase III Clinical Study for COVID-19 Drug; Share.. | |
| 02/01 | Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvi.. | |
| 02/01 | Chinese Regulator Accepts Shanghai Junshi Biosciences' New Drug Application for Migrain.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigationa.. | |
| 2022 | Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Vers.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 S.. | |
| 2022 | Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Dr.. | |
| 2022 | Shanghai Junshi's License Application for Nasopharyngeal Carcinoma Treatment Still Unde.. | |
| 2022 | Coherus BioSciences Shares Slip 9.6% on Lack of FDA Response to Toripalimab Application | |
| 2022 | Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Dr.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. and Hikma Pharmaceuticals PLC Sign Exclusive Lice.. | |
| 2022 | Junshi Biosciences Forms Licensing Deal With UK Drugmaker Hikma | |
| 2022 | Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License .. | |
| 2022 | Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License .. | |
| 2022 | Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License .. | |
| 2022 | Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA anti.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I stud.. | |
| 2022 | Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA anti.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes | |
| 2022 | Shanghai Junshi Raises 3.7 Billion Yuan From Issuance of A Shares | |
| 2022 | European Regulator Accepts Shanghai Junshi's Market Authorization Application for Lung .. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization A.. | |
| 2022 | Junshi Biosciences Announces Submission of a Marketing Authorization Application for To.. | |
| 2022 | Junshi Biosciences Announces Submission of a Marketing Authorization Application for To.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for To.. | |
| 2022 | Junshi Biosciences Announces Approval of Supplemental Application for Additional Indica.. | |
| 2022 | Chinese Regulator Approves Additional Indications for Shanghai Junshi's Adalimumab Inje.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Su.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization.. | |
| 2022 | Junshi Biosciences Announces Submission of a Marketing Authorization Application to the.. | |
| 2022 | Junshi Biosciences Announces Submission of a Marketing Authorization Application to the.. | |
| 2022 | Chinese Regulator Approves Shanghai Junshi Bioscience's A Share Issuance; Shares Climb .. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Tria.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ende.. | |
| 2022 | Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01,.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publicatio.. | |
| 2022 | Coherus, Junshi Publish Positive Results From Toripalimab Study | |
| 2022 | China Approves Supplemental New Drug Application for Junshi Biosciences' Lung Cancer In.. | |
| 2022 | Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with C.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in .. | |
| 2022 | Shanghai Bourse Deems Junshi Biosciences' A-Share Issuance Compliant with Listing Rules | |
| 2022 | Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Upda.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended .. | |
| 2022 | Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for J.. | |
| 2022 | Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigationa.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Tria.. | |
| 2022 | Chinese Regulator Accepts Shanghai Junshi Biosciences's Drug, Supplemental Applications | |
| 2022 | Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indi.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd Receives the Acceptance Notice for the Investigati.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental Appl.. | |
| 2022 | China approves Genuine Biotech's HIV drug for COVID patients | |
| 2022 | Shanghai Junshi Gets European Commission Designation for Nasopharyngeal Cancer Treatmen.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address with Effect from Augu.. | |
| 2022 | Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm.. | |
| 2022 | Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation fro.. | |
| 2022 | Chinese Regulator OKs Shanghai Junshi's Clinical Trial Application for Cancer Treatment | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Is.. | |
| 2022 | Shanghai Junshi's Resubmission of Biologics License Application for Toripalimab Gets US.. | |
| 2022 | Coherus BioSciences Says FDA Accepts Resubmission of Biologics License Application for .. | |
| 2022 | Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Torip.. | |
| 2022 | Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Torip.. | |
| 2022 | Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Accept.. | |
| 2022 | Coherus, Junshi: FDA Accepts Resubmission of Toripalimab Application | |
| 2022 | Shanghai Junshi Obtains FDA Investigational Drug Approval for Breast Cancer Treatment; .. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. and Risen Pharma Tech Co., Ltd. Announces FDA App.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director | |
| 2022 | Shanghai Junshi Biosciences Lowers Expected Total Proceeds for Proposed Issuance | |
| 2022 | Shanghai Junshi Biosciences Obtains Approval for Clinical Trial of EGFR Inhibitor Table.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) .. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) .. | |
| 2022 | Shanghai Junshi Gets Chinese Regulator's Approval for Clinical Trial of Investigational.. | |
| 2022 | Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Da.. | |
| 2022 | Junshi Biosciences JV Cleared to Start Clinical Trial in China of Cancer Drug | |
| 2022 | Chinese Shares Rebound; Junshi Jumps 4% in Shanghai as COVID-19 Tablet Finishes Clinica.. | |
| 2022 | VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Mod.. | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces PAXLOVID Phase III Registrational Trial.. | |
| 2022 | Junshi Completes Clinical Trials For COVID-19 Tablet | |
| 2022 | Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatme.. | |
| 2022 | Chinese Shares Rebound; Junshi Jumps 7.7% in Shanghai as COVID-19 Drug Shows Promise | |
| 2022 | Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea.. | |
| 2022 | Junshi Bio's Cancer Drug Wins New Indication in China; Shares Slide 7% | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Rapport
